Analysis of Costs per Responder in US Adults with Paroxysmal Nocturnal Hemoglobinuria with a Suboptimal Response to Prior Eculizumab Treatment

Analysis of Costs per Responder in US Adults with Paroxysmal Nocturnal Hemoglobinuria with a Suboptimal Response to Prior Eculizumab Treatment

European Society for Blood and Marrow Transplantation (EBMT) hematologic response categories comprehensively assess complement inhibitor responses in patients with paroxysmal nocturnal hemoglobinuria (PNH). Using data from the 16-week randomized controlled period of the phase 3 PEGASUS trial (N = 80...

Full description

Bibliographic Details
Main Authors: Jesse Fishman, Seri Anderson, Sandra E. Talbird, David Dingli
Format: Article
Language:English
Published: MDPI AG 2023-10-01
Series:Hematology Reports
Subjects:
paroxysmal nocturnal hemoglobinuria
pegcetacoplan
eculizumab
cost analysis
response analysis
Online Access:https://www.mdpi.com/2038-8330/15/4/60

Internet

https://www.mdpi.com/2038-8330/15/4/60

Similar Items